Compare Amphastar Pharmaceuticals Inc (AMPH) vs CleanSpark Inc (CLSK) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

CleanSpark (CLSK) trades at $12.85, down 0.31% on the day, with a bearish technical signal. The company reported strong 2025 revenue of $766 million and net income of $364 million, but forecasts a significant net loss of -$501 million for 2026. Recent operational updates highlight bitcoin mining activities and management team expansion, while analyst consensus remains unanimously bullish with a $21.43 price target.

The stock presents a high-risk, high-reward profile. Analyst optimism contrasts with negative earnings surprises and projected profitability challenges. Key risks include execution on growth initiatives, volatile cash flows, and intense competition in the data center sector. The current price offers substantial upside to targets if the company can achieve its operational goals.